IM 62 XX
Alternative Names: IM-62-XXLatest Information Update: 08 Dec 2023
At a glance
- Originator ITabMed
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 13 Oct 2023 Early research in Precursor B-cell lymphoblastic leukaemia-lymphoma in China (Parenteral) (ITabMed Pipeline, October 2023)